Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share

v3.22.1
Earnings Per Share
9 Months Ended
Mar. 31, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

Note 9. Earnings Per Share:

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

    

Quarter Ended

Nine Months Ended

March 31, 

March 31, 

    

2022

    

2021

2022

    

2021

Earnings per share – basic:

Net earnings, including noncontrolling interest

$

60,144

 

$

45,402

$

201,184

 

$

124,941

Less net earnings (loss) attributable to noncontrolling interest

(595)

 

(380)

(9,343)

 

(509)

Net earnings attributable to Bio-Techne

$

60,739

$

45,782

$

210,527

$

125,450

Income allocated to participating securities

 

(25)

 

(27)

 

(95)

 

(77)

Income available to common shareholders

$

60,714

$

45,755

$

210,432

$

125,373

Weighted-average shares outstanding – basic

 

39,272

 

38,856

 

39,225

 

38,693

Earnings per share – basic

$

1.55

$

1.18

$

5.36

$

3.24

Earnings per share – diluted:

 

  

 

  

 

  

 

  

Net earnings, including noncontrolling interest

$

60,144

$

45,402

$

201,184

$

124,941

Less net earnings (loss) attributable to noncontrolling interest

(595)

(380)

(9,343)

(509)

Net earnings attributable to Bio-Techne

$

60,739

$

45,782

$

210,527

$

125,450

Income allocated to participating securities

 

(25)

 

(27)

 

(95)

 

(77)

Income available to common shareholders

$

60,714

$

45,755

$

210,432

$

125,373

Weighted-average shares outstanding – basic

 

39,272

 

38,856

 

39,225

 

38,693

Dilutive effect of stock options and restricted stock units

 

1,697

 

1,820

 

1,848

 

1,612

Weighted-average common shares outstanding – diluted

 

40,969

 

40,676

 

41,073

 

40,305

Earnings per share – diluted

$

1.48

$

1.12

$

5.12

$

3.11

The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 0.8 million and 1.8 million for the quarter ended March 31, 2022 and 2021 respectively and 0.7 million and 1.6 million for the nine months ended March 31, 2022 and 2021 respectively.